Skip to main content
OBX
NASDAQ Life Sciences

Obsidian Posts Q3 Loss of $50.7M With $324.4M Cash and 67% ORR in Melanoma

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$12.48
Mkt Cap
$770.926M
52W Low
$9.6
52W High
$49.97
52W Position info
30% above low
Off High info
75% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

OBX sits 30% above its 52-week low of $9.6.

Summary

Obsidian reported a $50.7 million third-quarter net loss and $324.4 million in cash and securities, enough to fund operations into the second half of 2028, alongside the 67% ORR melanoma data presented at SITC and a new board appointment.


Key Events · Earnings and Guidance · OBX

  • Q3 Loss Widened by Galera Charge

    Net loss was $50.7 million, or $1.23 per basic and diluted share, for the three months ended September 30, 2026, including $15.1 million of acquired in-process R&D expense tied to the Galera transaction.

  • Cash Funds Operations Into 2H 2028

    Cash, cash equivalents and marketable securities totaled $324.4 million at September 30, 2026, which the company expects to support planned operations into the second half of 2028.

  • Melanoma Data: 67% ORR, 8.3-Month PFS

    In 15 patients treated at the recommended Phase 2 dose, amsoki-cel showed a 67% objective response rate (2 complete, 8 partial responses), median PFS of 8.3 months and median duration of response not reached at 14.3 months of follow-up.

  • Clean Pooled Safety Across 37 Patients

    No dose-limiting toxicities, treatment-related mortality, ICANS or ICU transfers were reported, with one Grade 3 cytokine release syndrome event.


Analysis · OBX · Life Sciences

The balance sheet is the headline: $324.4 million of cash and securities at September 30 funds operations into the second half of 2028, covering the registration-enabling Agni-01 readout management now guides to by year-end 2027. That removes any near-term financing need for a clinical-stage company burning roughly $38 million a quarter in R&D and G&A. On the clinical side, the 67% ORR and 8.3-month median PFS are the same figures already reported from SITC, but the filing adds the pooled safety set of 37 patients with no DLTs, no ICANS and no treatment-related deaths—the part regulators will weigh alongside efficacy. The quarter's loss was widened by a $15.1 million acquired IPR&D charge from the Galera transaction, a one-time item rather than a change in operating burn.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OBX was trading at $12.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $770.9M. The 52-week trading range was $9.60 to $49.97. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OBX - Latest Insights

OBX
Nov 12, 2026, 4:13 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.48
Real-time Price: $12.56 info
Change: +$0.080 (+0.64%) info
Market Cap: $775.867M info
OBX
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $12.48
Real-time Price: $12.56 info
Change: +$0.080 (+0.64%) info
Market Cap: $775.867M info
OBX
Aug 14, 2026, 4:29 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $19.00
Real-time Price: $12.56 info
Change: -$6.44 (-34%) info
Market Cap: $775.867M info
OBX
Aug 03, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $26.00
Real-time Price: $12.56 info
Change: -$13.44 (-52%) info
Market Cap: $775.867M info